Penserra Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Penserra Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-18	Closed	-$2K	–	1395
2023 Q3	$2K	Buy	18 +8	+80%	+$860	﹤0.01%	1208
2023 Q2	$1K	Hold	10	–	–	﹤0.01%	1253
2023 Q1	$1K	Buy	+10	New	+$1.1K	﹤0.01%	1091
2022 Q2	–	Sell	-16,707	Closed	-$1.76M	–	1567
2022 Q1	$1.76M	Buy	+16,707	New	+$1.63M	0.04%	361
2020 Q4	–	Sell	-12,404	Closed	-$963K	–	1172
2020 Q3	$963K	Buy	+12,404	New	+$853K	0.04%	271
2020 Q1	–	Sell	-4,554	Closed	-$155K	–	967
2019 Q4	$155K	Buy	+4,554	New	+$140K	0.01%	504
2019 Q1	–	Sell	-536,151	Closed	-$10.5M	–	826
2018 Q4	$10.5M	Buy	+536,151	New	+$10.5M	1.02%	28

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Penserra Capital Management's HZNP Position: Q4 2023 in Review

Penserra Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 18 shares — an estimated $2K sold.

Penserra Capital Management first reported a position in HZNP in Q4 2018 and held it in 7 quarters. The position peaked at $10.5M in Q4 2018. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Penserra Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Penserra Capital Management sold 18 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $2K.
Penserra Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2018 and held it in 7 quarters.
Penserra Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $10.5M in Q4 2018.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Penserra Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.